ClinicalTrials.gg
CompletedNCT01059318Updated Nov 19, 2020Results posted

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

A Phase 2 interventional study of Everolimus in Lymphangioleiomyomatosis, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Lymphangioleiomyomatosis with a site in United States — 6 open to participants now, 8 under way, 1 of them phase 3. Lymphangioleiomyomatosis · United States.

Enrollment
11th of 21
24 · median 24
Started
2010
the only one that year
Phase 2
8 of 28
none open now
Registered
10th of 28
by date
Lead sponsor
2 of 28
Novartis Pharmaceuticals

Among the 28 studies in Lymphangioleiomyomatosis with a site in United States, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2010, is one of 8 in phase 2, and was the 10th registered.

Lymphangioleiomyomatosis

49 studies on the registry are indexed under Lymphangioleiomyomatosis; 11 are open to participants now.

Browse Lymphangioleiomyomatosis studies →

Open to participants now

6 of the 28 studies in Lymphangioleiomyomatosis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Lymphangioleiomyomatosis studies recruiting now, 6 (60%) set no upper age limit and 1 (10%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Lymphangioleiomyomatosis with a site in United States, or all of them as a file.
02

Study summary

This was an exploratory study to determine whether escalating doses of RAD001 (everolimus) were safe and effective in patients with Lymphangioleiomyomatosis

Read the detailed description

In addition to the data collected in this study, historical data from 43 patients treated with placebo from the multicenter trial of sirolimus in LAM (MILES) study (NCT00414648) were down weighted to an effective sample size of 18 for comparison of FEV1 and FVC endpoints. Reference to the publication of the MILES study has been provided under "Result Publication".

03

Conditions studied

  • Lymphangioleiomyomatosis

Keywords

  • Lymphangioleiomyomatosis,
  • High Resolution CT scan,
  • chest x-ray,
  • 6 minute walk test,
  • pulse oximetry,
  • renal MRI,
  • Pikometer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female aged >/= 18 years with a diagnosis of LAM
  • Pulmonary function abnormalities as follows:
  • of ≤ 80% of the predicted value following administration of a standard dose of a short acting β2-agonist (*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) OR
  • FEV1 \< 90% of the predicted value of bronchodilator following administration of a standard dose of a short acting β2-agonist (*200 µg Salbutamol, measured between 10 and 15 minutes of inhalation) and DLco (uncorrected) \<80% predicted.
  • Female patients including those of will be included in this study.
  • Negative pregnancy test at screening and baseline

Exclusion criteria

Exclusion Criteria:

  • \<50% of predicted post-bronchodilator.
  • Change in FVC (ml) > ± 15% of screening value at baseline visit (not less than 14d after screening visit).
  • Use of any medicine containing estrogen in the 4 months prior to the screening visit and for the duration of the study
  • Significant hematologic, renal, hepatic laboratory abnormality or amylase > 1.5x the at the screening or baseline visits
  • Fasting blood glucose > 126mg/dl or random blood glucose >200mg/dl at screening and/or baseline
  • Recent surgery (involving entry into a body cavity or requiring sutures) within 2 months of the screening visit or any evidence of unhealed surgical wound.
  • Uncontrolled hyperlipidemia (defined as persistent elevation of total cholesterol or triglycerides >6.5nM/L) or a history of clinical atherosclerotic disease including heart attack, angina, peripheral vascular disease or stroke.
  • Previous organ transplantation
  • Inability to give
  • Inability to perform pulmonary function or 6 minute walk tests and imaging assessments

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Everolimus

    All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks. The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks.

    Drug: Everolimus

Interventions

  • Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.

    Also known as: RAD001

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations

    Blood samples (1 mL) for determination of VEGF-D were collected from a forearm vein (direct venipuncture or from an indwelling cannula) and 2 aliquots of serum were collected. VEGF-D levels were determined from only 1 of the 2 serum aliquots, with the second acting as a back-up. A serum VEGF-D \>800 pg/mL level supports a diagnosis of Lymphangioleiomyomatosis (LAM)

    Time frame: Baseline, 26 weeks

  2. Mean Trough (C0,ss) and Peak (C2,ss) Drug Concentration at Steady State

    Venous blood samples (2 mL) for pharmacokinetic evaluation were collected pre dose and 2 hours post dose at preselected visits.

    Time frame: pre-dose and at 2 hour post dose at week 26

Secondary outcomes

  1. Change From Baseline in Forced Vital Capacity (FVC)

    All spirometry evaluation followed recommendations of the Standardization of Lung Function Testing. All spirometry maneuvers were performed in sitting position whilst wearing nose clips. At least three acceptable maneuvers were performed for each time point, and results met within-test and between-test criteria for acceptability. The highest value was obtained of FVC from any of the three maneuvers that met acceptability criteria. Change from baseline in FVC was compared between everolimus and historical placebo data from multicenter trial of sirolimus in LAM. (MILES NCT00414648) due to absence of placebo group in this current study on a rare lung disease. These two studies had different study designs, so the change from baseline to 6 months (26 weeks) in MILES study was estimated from the publicly reported rate of change per month to provide a meaningful comparison. This historical control be can be viewed on the Novartis Clinical Trial Results website.

    Time frame: Baseline, 26 weeks

  2. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

    All spirometry evaluation followed the recommendations of the Standardization of Lung Function Testing. All spirometry maneuvers were performed in the sitting position whilst wearing nose clips. At least three acceptable maneuvers were performed for each time point, and the results met within-test and between-test criteria for acceptability. The highest value was obtained of FEV1 from any of the three maneuvers that met acceptability criteria. Change from baseline in FEV1 was compared between everolimus and historical placebo data from the MILES study (NCT00414648) due to the absence of a placebo group in this current study on a rare lung disease. These two studies had different study designs, so the change from baseline to 6 months (26 weeks) in MILES study was estimated from the publicly reported rate of change per month in order to provide a meaningful comparison. This historical control can be viewed on the Novartis Clinical Trial Results website.

    Time frame: Baseline, 26 weeks

  3. Change From Baseline in Extended Pulmonary Function Testing

    Extended pulmonary function testing such as Total Lung Capacity (TLC), Thoracic Gas Volume (TGV), Residual Volume (RV) were measured using a body plethysmograph

    Time frame: Baseline, 26 weeks

  4. Change From Baseline in Carbon Monoxide Diffusing Capacity (DLCO)

    Carbon Monoxide Diffusing Capacity (DLCO) one of the extended pulmonary function testing which was also measured using a body plethysmograph.

    Time frame: Baseline, 26 weeks

  5. Change From Baseline in 6-minute Walk Test Score to Measure Exercise Capacity

    A standardized 6-minute walk test (6MWT) was performed in accordance with the guidelines of the American Thoracic Society 2002. The test was done about the same time of day to avoid diurnal variation in an environment that had an adequate temperature to avoid additional burden to the patient due to heat or cold air. The distance walked in six minutes (6MWD) was recorded.

    Time frame: Baseline, 26 weeks

  6. Change From Baseline in Oxygen Saturation

    Oxygen saturation means the amount of oxygen in blood stream. Oxygen saturation was measured by using a Pulse Oximeter.

    Time frame: Baseline, 26 weeks

07

Results

Posted Nov 19, 2020

Participant flow

Core Study (26 Week)
Participant flow — Core Study (26 Week)
MilestoneEverolimus
Started24
Everolimus 2.5 mg for 4 weeks24
Everolimus 5 mg for 4 weeks24
Everolimus 10 mg for 18 weeks24
Pharmacokinetics (pk) analysis set16
Completed20
Not completed4
Withdrew: Adverse event3
Withdrew: Withdrawal by subject1
Extension (36 Week)
Participant flow — Extension (36 Week)
MilestoneEverolimus
Started20
Completed17
Not completed3
Withdrew: Adverse event3

Outcome measures

PrimaryChange From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations

Blood samples (1 mL) for determination of VEGF-D were collected from a forearm vein (direct venipuncture or from an indwelling cannula) and 2 aliquots of serum were collected. VEGF-D levels were determined from only 1 of the 2 serum aliquots, with the second acting as a back-up. A serum VEGF-D \>800 pg/mL level supports a diagnosis of Lymphangioleiomyomatosis (LAM)

Time frame:
Baseline, 26 weeks
Reported as:
Mean · pg/mL
Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations
pg/mLEverolimus 2.5 mg/DayEverolimus 5 mg/DayEverolimus 10 mg/Day
Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations-464.3 ± 745.23-1113.2 ± 1468.9-1771.7 ± 2091.6
PrimaryMean Trough (C0,ss) and Peak (C2,ss) Drug Concentration at Steady State

Venous blood samples (2 mL) for pharmacokinetic evaluation were collected pre dose and 2 hours post dose at preselected visits.

Time frame:
pre-dose and at 2 hour post dose at week 26
Reported as:
Mean · ng/mL
Mean Trough (C0,ss) and Peak (C2,ss) Drug Concentration at Steady State
ng/mLEverolimus 2.5 mg/DayEverolimus 5 mg/DayEverolimus 10 mg/Day
Trough (C0, ss)3.1 ± 1.335.8 ± 3.0211.0 ± 3.45
Peak (C2, ss)12.1 ± 3.5622.6 ± 7.2245.7 ± 12.52
SecondaryChange From Baseline in Forced Vital Capacity (FVC)

All spirometry evaluation followed recommendations of the Standardization of Lung Function Testing. All spirometry maneuvers were performed in sitting position whilst wearing nose clips. At least three acceptable maneuvers were performed for each time point, and results met within-test and between-test criteria for acceptability. The highest value was obtained of FVC from any of the three maneuvers that met acceptability criteria. Change from baseline in FVC was compared between everolimus and historical placebo data from multicenter trial of sirolimus in LAM. (MILES NCT00414648) due to absence of placebo group in this current study on a rare lung disease. These two studies had different study designs, so the change from baseline to 6 months (26 weeks) in MILES study was estimated from the publicly reported rate of change per month to provide a meaningful comparison. This historical control be can be viewed on the Novartis Clinical Trial Results website.

Time frame:
Baseline, 26 weeks
Reported as:
Mean · mL
Change From Baseline in Forced Vital Capacity (FVC)
mLEverolimus
Change From Baseline in Forced Vital Capacity (FVC)10 (-111 to 132)
Statistical analysis
  • Everolimus · Bayesian analysis · Mean difference (final values): 76 · 95% CI -45 to 196MILES study and current study had different study designs, so change from baseline to 26 weeks in MILES study was estimated from the publicly reported rate of change per month in order to provide a meaningful comparison based on Bayesian analysis.
SecondaryChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

All spirometry evaluation followed the recommendations of the Standardization of Lung Function Testing. All spirometry maneuvers were performed in the sitting position whilst wearing nose clips. At least three acceptable maneuvers were performed for each time point, and the results met within-test and between-test criteria for acceptability. The highest value was obtained of FEV1 from any of the three maneuvers that met acceptability criteria. Change from baseline in FEV1 was compared between everolimus and historical placebo data from the MILES study (NCT00414648) due to the absence of a placebo group in this current study on a rare lung disease. These two studies had different study designs, so the change from baseline to 6 months (26 weeks) in MILES study was estimated from the publicly reported rate of change per month in order to provide a meaningful comparison. This historical control can be viewed on the Novartis Clinical Trial Results website.

Time frame:
Baseline, 26 weeks
Reported as:
Mean · mL
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
mLEverolimus
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)114 (11 to 217)
Statistical analysis
  • Everolimus · Bayesian analysis · Mean difference (final values): 186 · 95% CI 93 to 279MILES study and current study had different study designs, so change from baseline to 26 weeks in MILES study was estimated from the publicly reported rate of change per month in order to provide a meaningful comparison based on Bayesian analysis.
SecondaryChange From Baseline in Extended Pulmonary Function Testing

Extended pulmonary function testing such as Total Lung Capacity (TLC), Thoracic Gas Volume (TGV), Residual Volume (RV) were measured using a body plethysmograph

Time frame:
Baseline, 26 weeks
Reported as:
Mean · Liters (L)
Change From Baseline in Extended Pulmonary Function Testing
Liters (L)Everolimus
TLC0.199 ± 0.8645
TGV0.267 ± 1.0368
RV0.169 ± 0.9055
SecondaryChange From Baseline in Carbon Monoxide Diffusing Capacity (DLCO)

Carbon Monoxide Diffusing Capacity (DLCO) one of the extended pulmonary function testing which was also measured using a body plethysmograph.

Time frame:
Baseline, 26 weeks
Reported as:
Mean · ml/min/mmHg
Change From Baseline in Carbon Monoxide Diffusing Capacity (DLCO)
ml/min/mmHgEverolimus
Change From Baseline in Carbon Monoxide Diffusing Capacity (DLCO)-0.782 ± 1.5351
SecondaryChange From Baseline in 6-minute Walk Test Score to Measure Exercise Capacity

A standardized 6-minute walk test (6MWT) was performed in accordance with the guidelines of the American Thoracic Society 2002. The test was done about the same time of day to avoid diurnal variation in an environment that had an adequate temperature to avoid additional burden to the patient due to heat or cold air. The distance walked in six minutes (6MWD) was recorded.

Time frame:
Baseline, 26 weeks
Reported as:
Mean · meters (m)
Change From Baseline in 6-minute Walk Test Score to Measure Exercise Capacity
meters (m)Everolimus
Change From Baseline in 6-minute Walk Test Score to Measure Exercise Capacity46.9 ± 115.30
SecondaryChange From Baseline in Oxygen Saturation

Oxygen saturation means the amount of oxygen in blood stream. Oxygen saturation was measured by using a Pulse Oximeter.

Time frame:
Baseline, 26 weeks
Reported as:
Mean · percentage of oxygen
Change From Baseline in Oxygen Saturation
percentage of oxygenEverolimus
Change From Baseline in Oxygen Saturation0.8 ± 2.13

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus—8/24 (33.3%)24/24 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventEverolimus
Oedema peripheralGeneral disorders2/24
Cardiac failureCardiac disorders1/24
PericarditisCardiac disorders1/24
TachycardiaCardiac disorders1/24
Non-cardiac chest painGeneral disorders1/24
PyrexiaGeneral disorders1/24
BronchitisInfections and infestations1/24
Pneumocystis jiroveci infectionInfections and infestations1/24
PneumoniaInfections and infestations1/24
NephrolithiasisRenal and urinary disorders1/24
Most frequent other events
Showing 10 of 48
Most frequent other events
EventEverolimus
Mouth ulcerationGastrointestinal disorders11/24
HeadacheNervous system disorders9/24
DiarrhoeaGastrointestinal disorders7/24
NauseaGastrointestinal disorders7/24
StomatitisGastrointestinal disorders7/24
FatigueGeneral disorders7/24
CoughRespiratory, thoracic and mediastinal disorders7/24
Oropharyngeal painRespiratory, thoracic and mediastinal disorders7/24
Oedema peripheralGeneral disorders6/24
Aphthous stomatitisGastrointestinal disorders5/24

Baseline characteristics

Everolimus arm has all patients who received study drug that is the safety analysis set.

Age, Continuous
Age, Continuous(years)Everolimus
Mean44 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus
Female24
Male0
08

Study locations

4 sites
  • Center for LAM Research and Clinical Care
    Boston, Massachusetts 02115, United States
  • University of Cincinnati, Department of Internal Medicine, Pulmonary, Critical Care & Sleep Medicine,
    Cincinnati, Ohio 45267, United States
  • Novartis Investigative Site
    Lyon, France
  • Novartis Investigative Site
    Milan, Italy
09

References and documents

Publications

  • McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011 Apr 28;364(17):1595-606. doi: 10.1056/NEJMoa1100391. Epub 2011 Mar 16. PubMed 21410393 ↗
  • Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, Cheng Y, Khindri S, Kovarik JM, Ma S, McCormack FX, Henske EP. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015 Sep;46(3):783-94. doi: 10.1183/09031936.00210714. Epub 2015 Jun 25. PubMed 26113676 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 8 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2010
First posted
Jan 29, 2010
Start
Jan 2010
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Nov 19, 2020
Last update
Nov 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01059318
Responsible party
Sponsor
First posted
Jan 29, 2010
Start date
Jan 2010
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Nov 19, 2020
Last update
Nov 19, 2020

Study contacts

Novartis
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion